The Platform Shift: AI, Genomics, and the Patent Cliff Transforming Biotech M&A

Marketing Communication. Capital at Risk. For Professional Investors Only.

Pharmaceutical giants face an unusual problem: too much capital, not enough time. Between 2026 and 2030, roughly 190 branded drugs will lose patent protection, erasing up to an estimated $400 billion in annual sales.¹ The typical response to this problem is that internal R&D takes too long. Internal R&D takes a decade on average but patents start expiring in 2026, so Big Pharma is buying innovation instead of developing it, and it is what they are buying which has fundamentally changed.²

The $12 billion Novartis paid for Avidity Biosciences wasn’t for a single drug.³ It was for RNA delivery infrastructure, a platform that could generate multiple therapies across different diseases.⁴ Pharmaceutical companies are no longer just backfilling pipelines with late-stage assets but acquiring the technologies that are reshaping how medicine works, from AI-driven drug discovery, liquid biopsy platforms, genomic sequencing at scale to neuroscience and rare disease portfolios.⁵

Key Takeaways:

• Genomics is Becoming Infrastructure, Not Research – Falling sequencing costs, liquid biopsy diagnostics, and rapid CRISPR therapy development have moved precision medicine from the research lab to increasingly routine clinical use, with adoption accelerating across oncology and rare disease.⁶
• AI Is Compressing Drug Development Timelines and Delivering Clinical Proof – AI-designed drug candidates are now entering human trials at an accelerating rate, with first FDA Phase 2a efficacy results in 2025 validating computational approaches.⁷
• Patent Super Cliff Pressures Appear to be Reshaping Biotech M&A – With roughly 190 drugs losing exclusivity by 2030, pharmaceutical companies are racing to acquire rather than develop.⁸ Deal volumes surged 81% in 2025, with capital concentrating on RNA therapeutics, AI-driven discovery platforms, and genomic diagnostics.⁹,¹⁰

Genomics is Becoming Infrastructure, Not Research

The Turning Point

2025 saw the first patient treated with a personalised gene based-editing therapy (CRISPR) designed specifically for his unique mutation in just six months.¹¹ The FDA subsequently outlined regulatory pathways for such “N-of-1” therapies, validating the shift toward individualised genetic medicine.¹² This may represent a convergence of three critical breakthroughs that appear to be reshaping the pharmaceutical industry.

The foundation was economic. When Illumina’s NovaSeq X series crossed the sub-$200 genome threshold in 2023, genetic sequencing transformed from a research tool into something scalable for everyday medicine.¹³

Illumina controls over 80% of the next-generation sequencing market, and its December 2025 partnership with MyOme targeting the Million Person Health Trial, combines genetic sequencing with AI models to predict disease onset 5-10 years before symptoms appear.¹⁴,¹⁵ Economic models suggest this preventive approach could save over $200 billion annually in US healthcare costs.¹⁶

But sequencing data is only as valuable as the sample behind it. Several companies are making breakthroughs in this area. Qiagen’s tools turn raw tissue and blood samples into actionable data. Its QIAseq panels profile tumours and blood cancers comprehensively, powering companion diagnostics for more than 15 FDA‑approved targeted therapies.¹⁷ Bio-Techne supports the next layer of discovery, supplying reagents for genomics and proteomics that accelerate drug development and diagnostics research.¹⁸ Its focus on spatial biology and single-cell analysis, boosted by the Lunaphore acquisition, lets scientists map 100+ biomarkers in a single tissue section, revealing how cells interact in ways traditional tests cannot.¹⁹Together, these companies form the infrastructure on which the precision medicine is built.

Clinical Transformation: From Tissue to Blood

That infrastructure also unlocked a parallel transformation in diagnostics. Illumina’s sequencing technology made liquid biopsy viable at scale: instead of invasive tissue samples, doctors can now analyse tumour DNA fragments shed into the bloodstream through a simple blood draw.²⁰,²¹,²² The technology detects genetic changes across an entire genome from a single sample, something that would have been impossible with older, slower, and more expensive sequencing methods.

Clinical adoption is accelerating. In June 2025, the FDA granted Breakthrough Device designation to Guardant Health’s Shield test, which detects early-stage cancers across multiple types with 87% accuracy.²³ For patients already undergoing treatment, Natera’s Signatera platform monitors tumour DNA levels in the blood to track whether therapy is actually working.²⁴ The platform distinguishes tumour DNA from normal cellular debris through advanced computational analysis, giving oncologists a real-time view of disease status without repeated biopsies.²⁵

Natera sharpened this capability further with its December 2025 acquisition of Foresight Diagnostics, which brought technology that increased detection sensitivity tenfold.²⁶ That means earlier detection of recurrence, often before traditional imaging would catch it.

Therapeutic Innovation: RNA’s Two Paths

While CRISPR permanently edits genes, RNA therapeutics offer a more flexible approach. Rather than rewriting the genetic blueprint, they modulate how that blueprint is expressed, allowing treatment to be tuned over time.²⁷ The technology comes in two forms:

mRNA: Adding Instructions

Validated by COVID-19 vaccines, mRNA technology is now expanding into cancer and rare diseases. Instead of editing genes, it delivers temporary instructions for cells to produce specific proteins.²⁸ Moderna has personalised cancer vaccines in Phase 3 trials, with melanoma (skin cancer) data expected in H1 2026.²⁹ Analysts project the global mRNA market size to reach north of $30 billion by 2030, growing at a CAGR of 17% from 2023 base levels.³⁰

RNAi: Silencing Instructions.

RNA Inference (RNAi) works the opposite way by shutting down disease-causing genes before they can produce harmful proteins.³¹ November 2025 marked a turning point, when Arrowhead Pharmaceuticals received FDA approval for Redemplo (plozasiran), its first approved product.³² The drug treats a rare genetic disease affecting approximately 6,500 US patients who have dangerously high triglyceride levels (a type of fat found in blood) that can cause life-threatening complications.³³ In clinical trials, the treatment reduced triglycerides by 80%.³⁴ The approval triggered rapid global expansion, with China approving the drug in January 2026, followed by Health Canada.³⁵ More importantly, the FDA granted Breakthrough Therapy designation in December 2025 for the same drug to treat millions of patients worldwide with severe triglyceride elevation.³⁶

The Scaling Challenge: From Laboratory to Patient

The first patient case demonstrated what’s possible under gene editing technology, but it also exposed the central challenge: personalised genetic medicine only works if it can scale beyond one-off heroic interventions. Traditional CAR-T cancer therapy costs over $500,000 per patient and requires weeks of specialised manufacturing, limiting it to the most severe cases.³⁷

The industry is now pivoting toward “in vivo” approaches where genetic modifications happen directly inside the patient’s body rather than in a laboratory, dramatically reducing both time and cost.³⁸ Companies like REGENXBIO are developing long-acting gene therapies that act as ‘biofactories’ inside the body which are designed to deliver sustained therapeutic benefit from a single administration, replacing the need for repeated treatment.³⁹

AI Is Compressing Drug Development Timelines and Delivering Clinical Proof

Clinical Validation of AI Designed Molecules

By 2025, AI had moved from experimental promise to a validated drug discovery platform.⁴⁰ The first Phase 2a results from fully AI-designed molecules showed clinical efficacy, and from virtually no AI-designed drugs in trials in 2020, dozens had entered human testing by mid-2025, with progression rates comparable to traditional discovery.⁴¹,⁴² A prime example is Insilico Medicine, a Boston-based company that uses AI to pursue a treatment for idiopathic pulmonary fibrosis (IPF), a deadly disease that ravages lung tissue with thick, stiff scars.⁴³ One AI system identified a previously unknown protein involved in causing the disease; a second designed a molecule to block it.⁴⁴ That molecule became a drug named rentosertib, which has since shown promising safety and efficacy results in early human trials reported last June.⁴⁵,⁴⁶

This kind of timeline compression is emerging as the defining pattern across the industry. Moderna employs machine learning to optimise mRNA sequences for stability and immunogenicity, cutting candidate selection from 18 months to 6 months.⁴⁷ Illumina’s DRAGEN platform uses AI to reduce 30-hour whole genome analysis to under 30 minutes.⁴⁸ Guardant Health and Natera deploy AI models that distinguish tumour-derived DNA from background noise, achieving sensitivity improvements of 3-5x over conventional methods.⁴⁹ Vertex uses computational chemistry and machine learning to predict small molecule interactions, accelerating lead optimisation for cystic fibrosis and pain therapies.⁵⁰ The applications vary but the underlying dynamic is consistent, in that AI is collapsing timescales that were previously fixed.

Solving the Data Bottleneck

Pharmaceutical companies have responded by building infrastructure. GPU-based supercomputers purpose-built for drug discovery began coming online in early 2026.⁵¹ Eli Lilly partnered with NVIDIA to launch TuneLab, an end-to-end AI platform designed to accelerate molecular discovery and compress drug development cycles that currently average ten years.⁵² They aren’t alone, with multiple companies now integrating AI throughout their discovery platforms.⁵³

Scaling these capabilities, however, depends on solving persistent data problems. Publicly available structural biology databases contain gaps and errors that limit model precision, and proprietary industry datasets have historically remained siloed.⁵⁴ The AI Structural Biology Network (AISB) represents one attempt to change this through a federated collaboration where major biopharmaceutical companies pool proprietary structural biology data to train AI models while keeping each partner’s data confidential.⁵⁵ Major biopharmaceutical companies, including Bristol Myers Squibb and AstraZeneca, pool proprietary structural biology data to train shared AI models while keeping each partner’s data confidential.⁵⁶,⁵⁷ Designed specifically for drug development rather than basic research, AISB uses federated learning to train AI models on pooled proprietary industry data, with OpenFold3 as its flagship model.⁵⁸

Even the most precisely discovered therapies, though, cannot reach patients without a corresponding revolution in manufacturing. The industry has begun to address this through what it calls Bioprocess 5.0, where it integrates AI, automation, and digital twins (virtual simulations of production environments) to manufacture complex biologics with unprecedented consistency and speed.⁵⁹ Rather than relying on trial-and-error, AI optimises manufacturing parameters in real time, while digital simulations allow changes to be tested without risking actual production runs. As personalised therapies expand from individual patients to broader populations, this infrastructure becomes essential, resolving the same manufacturing bottleneck that once severely limited the early rollout of CAR-T therapy.⁶⁰

Patent Super Cliff Pressures Appear to be Reshaping Biotech M&A

The Looming Patent Cliff

Between 2026 and 2030, an estimated $236 billion to $400 billion in annual branded prescription drug sales face loss of exclusivity as roughly 190 drugs, including 69 blockbusters with annual sales exceeding $1 billion each, come off patent.61 The exposure is concentrated at the top with Merck’s Keytruda ($23.3 billion in Q1-Q3 2025 alone), Bristol Myers Squibb’s Eliquis (projected sales declines of $1.5 to $2.5 billion in 2027), and Novartis’ Entresto (part of a $4 billion revenue gap expected in 2026 from multiple patent losses).⁶¹,⁶²,⁶³,⁶⁴,⁶⁵ This “super-cliff” is widely regarded as the largest cyclical patent expiration wave the industry has faced, potentially dwarfing the 2011-2016 cliff that saw drugs like Lipitor and Singulair lose exclusivity.⁶⁶ Faced with that pressure, pharmaceutical companies have responded not by accelerating internal R&D, which averages a decade, but by buying innovation.

The Buying Spree Began in 2025

Following a slow start due to U.S. tariff uncertainty, FDA leadership changes, and President Trump’s most favoured nation pricing executive order, biotech M&A picked up momentum in late 2025.⁶⁷ Of the top 10 biopharma M&A deals in 2025, 6 came in the fourth quarter.⁶⁸ 2025 total deal volume reached approximately $240 billion for the full year, representing an 82% surge, with multiple megadeals exceeding $5 billion compared to zero in 2024.⁶⁹,⁷⁰

Strategic Shift: Bolt-On Over Blockbuster

The strategic shape of dealmaking has also changed. Rather than pursuing horizontal mega-mergers that attract FTC scrutiny, pharmaceutical companies are executing multiple smaller “bolt-on” acquisitions.⁷¹ These deals target late-stage clinical assets or recently approved drugs that can be integrated into existing commercial infrastructure without lengthy development timelines.⁷² Large pharmaceutical companies entered 2025 with substantial balance-sheet capacity, with the top 25 firms collectively holding approximately $1.3-1.4 trillion in deployable capital.⁷³ Industry experts anticipate this trend will continue through 2026 and 2027, with 20 or more acquisitions potentially exceeding $1 billion anticipated.⁷⁴

What has changed most is what companies are buying. The approximately $12 billion acquisition of Avidity Biosciences by Novartis clearly illustrates this strategic shift.⁷⁵ The deal wasn’t primarily about backfilling a single product gap, but about acquiring RNA delivery infrastructure capable of generating multiple therapies across different indications and disease areas.⁷⁶ That platform logic, buying the technology rather than just the drug, now defines most deals in the sector.⁷⁷

Three therapeutic areas dominated 2025 dealmaking, each for distinct reasons. Neuroscience staged a notable comeback with the two largest transactions of the year with Johnson & Johnson’s acquisition of Intra-Cellular and Novartis’ purchase of Avidity.⁷⁸ This represents an “absolute diversion from past trends when oncology dominated,” according to EY Americas life sciences leader Arda Ural.⁷⁹ Advances in RNA therapeutics, gene therapy, and biomarker-driven patient selection are reigniting confidence in central nervous system drug development.⁸⁰ Cardiometabolic assets emerged as a second battleground, fuelled by the GLP-1 revolution and the competitive urgency it has created, as illustrated by the Pfizer-Novo bidding war over Metsera.⁸¹,⁸² Rare diseaseretained its enduring appeal, with Sanofi’s Blueprint acquisition reflecting the continued attraction of genomically defined patient population and the favourable pricing dynamics they support.⁸³

Looking Ahead

Looking ahead, the conditions that drove last year’s activity remain intact.⁸⁴ The abundance of capital combined with the urgency created by the patent cliff creates a potentially favourable environment for innovative biotech companies with differentiated assets.

Analysts forecast 15% growth in both deal value and count for 2026.⁸⁵ Goldman Sachs anticipates record M&A across sectors, predicting roughly $3.9 trillion total global deal flow.86 Within biopharma, nearly 520 deals worth $230 billion are projected.⁸⁷ Supporting factors include: 1) the persistent patent cliff pressure, 2) reduced US market uncertainty following pharma-administration pricing agreements, 3) Fed rate cuts lowering capital costs, and 4) biotech valuations recovering from spring 2025 lows.⁸⁸

This document is not intended to be, or does not constitute, investment research as defined by the Financial Conduct Authority.